Study of Liraglutide and Metformin to Improve Pregnancy Rates in Obese Women with PCOS Undergoing IVF-FET

What this Trial Is About

Researchers are evaluating the effects of liraglutide, a hypoglycemic drug approved for treating obesity, on obese women with polycystic ovary syndrome PCOS who have infertility issues and are undergoing in vitro fertilization-frozen embryo transfer IVF-FET. PCOS is a leading cause of female anovulatory infertility and is often linked with obesity. The study aims to test whether liraglutide treatment before embryo transplantation can reduce weight and improve live birth rates in this group. Participants are divided into two groups one receiving liraglutide 3.0 mg or the maximum tolerable dose daily plus metformin 1500 mg daily, and the other receiving metformin 1500 mg daily alone. Liraglutide treatment lasts 12 weeks before pregnancy, while metformin continues until pregnancy. This randomized controlled trial compares these treatments to assess their impact on reproductive outcomes. During the study, researchers will monitor live birth rates from a single frozen embryo transfer cycle as the primary outcome. Secondary outcomes include clinical pregnancy rates, incidence of diabetes during pregnancy, pregnancy complications, birth weight, Apgar scores, and other perinatal outcomes. Participants will be followed from baseline through delivery, and additional follow-up will assess accumulated live birth and clinical pregnancy rates at six months. The total participation duration varies with pregnancy and delivery timelines.

Liraglutide Treatment in Obese Infertile PCOS Women